Medtronic Plc agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said.
Impressive top-line results were reported from a pivotal Phase II study for the PD-1 inhibitor cemiplimab.
Daiichi Sankyo Europe GmbH informed Nektar Therapeutics that it was terminating a collaboration and licensing deal, which becomes effective Feb. 4, 2018. All rights and licenses that Daiichi acquired in the deal will revert to Nektar.
Johnson & Johnson topped the Bioethics International “Good Pharma Scorecard” for the second year in a row.
At least half the world’s population is unable to access essential health services and many others are forced into extreme poverty by having to pay for healthcare they cannot afford, the World Health Organization said.
Eli Lilly and Company today announced its 2018 financial guidance, including low-single-digit revenue growth driven by volume from recently launched pharmaceutical products. The company also highlighted key events for 2018, including continued progress on Lilly’s pipeline.
Sanofi management expressed confidence that the company’s pipeline of new products will support long-term growth.
U.S. House Republicans proposed to delay or suspend several taxes under former President Barack Obama’s healthcare law, including a tax on medical devices and the so-called “Cadillac” tax on generous health insurance plans.
Allergan is buying Repros Therapeutics for $0.67 per share. The deal is expected to close in the first quarter of 2018.
Privately held Dart NeuroScience and its quest to develop therapies intended to improve cognitive vitality will close its doors on Feb. 9, 2018, due to poor progress on the San Diego-based company’s therapeutic goals and little return on hundreds of millions of dollars in research and development.